Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DaVita Inc. stock logo
DVA
DaVita
$136.35
-0.4%
$139.55
$131.76
$179.60
$10.34B1.11805,512 shs1.02 million shs
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$71.89
-0.1%
$69.07
$60.56
$82.49
$8.76B0.861.71 million shs1.89 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$125.80
-0.6%
$116.55
$84.23
$157.98
$12.52B0.241.14 million shs1.06 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.33
$19.45
$31.79
$2.77B0.731.26 million shsN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DaVita Inc. stock logo
DVA
DaVita
0.00%+0.54%-1.19%-9.23%-3.34%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.00%+2.55%+0.46%+1.72%+7.02%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.74%+5.30%+9.47%-5.96%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%0.00%+0.42%+28.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DaVita Inc. stock logo
DVA
DaVita
4.4312 of 5 stars
2.01.00.04.52.81.74.4
Henry Schein, Inc. stock logo
HSIC
Henry Schein
3.541 of 5 stars
2.31.00.03.42.71.71.9
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.7204 of 5 stars
4.43.00.02.92.12.51.9
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.3318 of 5 stars
1.00.02.51.70.01.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DaVita Inc. stock logo
DVA
DaVita
2.00
Hold$164.5020.65% Upside
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.64
Moderate Buy$79.3010.31% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.86
Moderate Buy$162.0028.78% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside

Current Analyst Ratings Breakdown

Latest HSIC, PDCO, NBIX, and DVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$145.00
5/19/2025
DaVita Inc. stock logo
DVA
DaVita
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$170.00 ➝ $164.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $75.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$90.00 ➝ $86.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$137.00 ➝ $152.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$155.00 ➝ $165.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$138.00 ➝ $139.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DaVita Inc. stock logo
DVA
DaVita
$12.97B0.79$19.04 per share7.16$4.83 per share28.23
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.69$7.32 per share9.82$32.33 per share2.22
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.36B5.29$3.36 per share37.44$25.58 per share4.92
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DaVita Inc. stock logo
DVA
DaVita
$936.34M$10.0913.5110.730.946.63%176.11%4.66%8/5/2025 (Estimated)
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.2022.4714.322.323.21%14.87%5.82%8/5/2025 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$341.30M$2.9542.6419.441.3012.68%11.81%8.59%7/30/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%8/26/2025 (Estimated)

Latest HSIC, PDCO, NBIX, and DVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
DaVita Inc. stock logo
DVA
DaVita
$1.75$2.00+$0.25$2.00$3.22 billion$3.22 billion
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
5/5/2025Q1 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$0.70$0.08-$0.62$0.08$587.06 million$572.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DaVita Inc. stock logo
DVA
DaVita
N/AN/AN/AN/AN/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DaVita Inc. stock logo
DVA
DaVita
23.18
1.25
1.20
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.50
1.38
0.75
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
3.13
3.02
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76

Institutional Ownership

CompanyInstitutional Ownership
DaVita Inc. stock logo
DVA
DaVita
90.12%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%

Insider Ownership

CompanyInsider Ownership
DaVita Inc. stock logo
DVA
DaVita
2.00%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.14%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.30%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
DaVita Inc. stock logo
DVA
DaVita
76,00075.50 million73.99 millionOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.72 million120.33 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,80098.97 million94.71 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable

Recent News About These Companies

Erin Patterson’s liposuction testimony
Camp Patterson campaign kicks off

New MarketBeat Followers Over Time

Media Sentiment Over Time

DaVita stock logo

DaVita NYSE:DVA

$136.35 -0.59 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$136.24 -0.10 (-0.08%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$71.89 -0.09 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$71.89 0.00 (0.00%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$125.80 -0.75 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$125.28 -0.52 (-0.42%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.